Johnson & Johnson stock analysis 2026: 2.07% yield warning

↓ Download the full research PDF · free, no email required

Johnson & Johnson stock analysis 2026: 2.07% yield warning

Business Quality Assessment

This Johnson & Johnson stock analysis begins by assessing the two healthcare engines. Innovative Medicine produced $60.4 billion of fiscal 2025 revenue, up 6.0%, while MedTech reported a 12.2% operating margin for the same period, per the fiscal 2025 10-K. The company holds a Wide Moat with a Stable trend and Low Uncertainty rating from StockIntent as of the latest research review. Regulatory barriers in pharmaceuticals and switching costs in medical devices protect the economics.

The growth evidence is concentrated in oncology and cardiovascular technology. In fiscal 2025, Oncology grew 22% on Darzalex and Carvykti, and Electrophysiology grew 16%, per the same annual report. Innovative Medicine posted a 36.9% operating margin, while MedTech’s 12.2% margin remains the lower-margin segment. Operational sales rose 6.4% in the first quarter of 2026, and management raised full-year guidance after that report, according to the company’s investor relations disclosure. The fiscal 2025 10-K confirms United States sales of $53.8 billion against international sales of $40.4 billion.

The moat is durable, but the growth story has offsets. Stelara faces biosimilar competition, Opsumit generics arrive in 2026, and Xarelto loses exclusivity in 2027. The pipeline includes Icotyde, Imaavy, Inlexzoh/TAR-200, and Rybrevant plus Lazcluze, but MedTech must still prove faster expansion. Our Wealth Preservation methodology values stability over a 30% year-to-date chase.

Financial Fortress Analysis

This Johnson & Johnson stock analysis next examines the balance sheet. Yahoo Finance shows TTM EBITDA of $34.87 billion. The fiscal 2025 10-K reports $47.9 billion of total debt and $20.1 billion of cash. Net debt of $27.8 billion equals 0.80 times EBITDA. Gross debt to EBITDA is 1.37. Cash covers 42% of total debt.

Free cash flow is the key preservation metric. The free cash flow margin near 20.4% on $97.93 billion of TTM revenue implies about $20 billion of annual free cash flow. The dividend requires about $12.9 billion per year. That produces 1.55 times dividend coverage. The payout ratio sits near 46% of adjusted EPS guidance of $11.60 to $11.75 for 2026. These are forward-looking estimates based on the latest filings and management guidance.

A stress test supports the fortress classification. If revenue dropped 30% over two years, gross profit would likely remain positive at a 68% gross margin. Johnson & Johnson has not cut the dividend in 64 years, including the 2008 and 2020 downturns. We classify solvency as fortress on leverage metrics, with adequate note until stricter liquidity ratios are certified. Based on current cash flow and balance sheet estimates, the company does not appear to require equity market issuance to fund operations, research, or litigation reserves. This is an estimate, not a guarantee.

Johnson & Johnson stock analysis: dividend review

Johnson & Johnson pays $1.34 per share quarterly, or $5.36 annually. At the current price of $258.45, the dividend yield is 2.07%. The company raised the quarterly dividend 3.1% to $1.34, marking 64 consecutive years of increases according to Simply Wall St. That is the longest continuous growth record among large-cap healthcare companies in the research package.

Payout safety appears strong. On 2026 adjusted EPS guidance of $11.60 to $11.75, the payout ratio is about 46%. On TTM GAAP EPS of $8.63, the payout is 62.1%. The free cash flow payout ratio runs near 64.6%, based on the latest quarterly filing and management guidance. All three measures sit below the framework’s 70% to 85% red-line threshold.

The income problem is growth. The latest increase of 3.1% falls below the 5% CAGR most income investors need for real compounding. At $220, the yield would rise to 2.44% and provide a more acceptable total income base. We estimate dividend sustainability as high, subject to litigation and operational risks. A credible caveat is that unexpected litigation costs could slow future increases to 2% or less without breaking the payout.

Johnson & Johnson stock analysis: valuation discipline

The stock is expensive relative to its own history. Based on TTM GAAP EPS of $8.63 and the latest share price of $258.45, the trailing P/E is about 29.95. Yahoo Finance lists forward P/E of 20.75, price/book of 7.53, and EV/EBITDA of 19.68. On June 30, 2025, EV/EBITDA was 10.98 and price/book was 4.71. The multiple expansion followed a move from about $199 in early January 2026 to $258.45 as of the latest market close, a roughly 30% year-to-date gain.

The historical comparison is unambiguous. Fullratio reports a healthcare sector average P/E of 23.23. Public.com year-end P/E figures show a five-year average near 24.06. The current trailing P/E of 29.95 sits above both. Our base case uses a conservative normalized forward EPS of $12.45 and a 19.5 multiple to reach $243 fair value.

At $258.45, the company trades 6.0% above fair value. The valuation gate scores zero points out of fifteen because the stock sits above the 75th percentile of its five-year range. A preservation investor should not pay up for quality after a 30% run. The $220 threshold restores the modeled margin of safety. This threshold is a scenario output, not a recommendation.

Scenario Analysis and Probability-Weighted Return

This Johnson & Johnson stock analysis uses a ten-year horizon with three scenarios. All scenario figures are forward-looking estimates subject to model, market, and litigation risks. The normalized forward EPS base is $12.45 and the current annual dividend is $5.36.

Bear case, 25% weight: recession hits in 2027, patent losses arrive together, MedTech margin stalls, and litigation intensifies. Revenue grows 1% annually, EPS reaches about $14.45, and the forward P/E contracts to 15.0. The terminal price is $217, plus $53.60 of dividends. Total return CAGR is 0.5%.

Base case, 50% weight: revenue grows 6% to 7%, EPS compounds at 7.0%, and the multiple reverts to 19.0. Terminal EPS of $24.49 produces a terminal price of $465 with $66.90 of collected dividends. Total return CAGR is 7.5%, which meets but barely clears the 7% hurdle.

Bull case, 25% weight: OTTAVA, Shockwave, and Abiomed accelerate MedTech. EPS compounds at 9.5% to $30.85, and the multiple holds at 22.0. Terminal price is $679, and total return CAGR is 11.3%. The probability-weighted return is 6.7%, slightly below the 7% target. That gap drives the Hold classification.

Risk Assessment: Johnson & Johnson stock analysis

Permanent-loss risk remains low. The company has a diversified two-segment model, net debt to EBITDA of 0.80, 64 years of dividend increases, and an estimated $20 billion free cash flow stream. Talc litigation remains the most cited headline risk. The Seeking Alpha coverage notes the March 5 decline tied to the Bayer v. Janssen lawsuit and talc concerns. The 10-K includes a dedicated section on product liability and regulatory activity.

Patent cliff risk exists but remains manageable. The company replaced $913 million of lost sales with $2.4 billion of new sales, but kept less than half after offsets. The pipeline has credible assets, yet MedTech margin of 12.2% sits far below Innovative Medicine at 36.9%. Mix shift toward devices dilutes returns unless margins expand. Our Abbott Laboratories stock analysis highlighted similar device margin dynamics.

Valuation risk remains the core concern. If the market re-rates the trailing P/E back to the five-year average near 24.06, the stock would fall from current levels even without operational deterioration. The company lacks a clean acceleration story to justify $258.45. The recession profile remains resilient because oncology and immunology demand does not disappear in a downturn. We estimate the probability of a permanent capital loss above 50% at below 5% under the base scenario.

Management and Governance Review

Joaquin Duato has led Johnson & Johnson as CEO since January 2022. Under his leadership, the company completed the Kenvue separation, acquired Abiomed, Shockwave Medical, Intra-Cellular Therapies, and Halda Therapeutics, and announced the Sail Biomedicines collaboration. The Sail transaction involves $785 million of initial payments and could dilute adjusted EPS by $0.18 in 2026 and $1.28 in 2027, per the company’s disclosures.

Management raised guidance after the first-quarter 2026 report. The most recent quoted quarter reported sales of $25.3 billion and adjusted EPS of $2.90 above consensus, based on the company’s earnings release. The company now guides to $100.8 to $101.4 billion of reported sales and $11.60 to $11.75 of adjusted EPS. Recent insider activity is routine, consisting of option exercises and tax withholding sales, with no material open-market purchases disclosed in the latest filings.

Capital allocation is acceptable but aggressive. Total debt reached $47.9 billion after debt-funded acquisitions. The company invested more than $32 billion in R&D and M&A in 2025. We rate management quality good and capital allocation acceptable. The MedTech margin gap and the pace of debt-funded deals offset the positive dividend record.

Peer Comparison: Johnson & Johnson vs Healthcare Sector

This Johnson & Johnson stock analysis compares the company to sector benchmarks rather than individual peer financials. Fullratio reports a healthcare sector average P/E of 23.23. Johnson & Johnson’s trailing P/E of 29.95 is about 29% above that sector average. The company’s net debt to EBITDA of 0.80 and free cash flow margin of 20.4% are sector-leading.

StockIntent’s moat assessment places Johnson & Johnson as a Wide Moat with Low Uncertainty. The company ranks number one or number two in 65% of its segments. That is a stronger competitive statement than most healthcare peers. We scored Abbott Laboratories separately on similar device margin pressure, but this company has a longer dividend record and larger free cash flow base. Our UnitedHealth Group stock analysis covers a different healthcare vertical with different payer economics.

Quality relative to peers is not the issue. The stock re-rated sharply and trades above both the sector and its own five-year average. A premium business at a fair price beats a discount business at a cheap price. This price sits slightly above fair value.

For educational transparency, Angelos Moschovakis maintains a public eToro Popular Investor profile. Reviewing the portfolio provides context on how research themes translate into a real allocation. Copy trading involves significant risk and does not amount to investment advice. Past performance is not indicative of future results.

Monitoring Checklist and Consensus Expectations

This Johnson & Johnson stock analysis tracks a monitoring checklist showing nine passes and two fails. Debt to equity, net debt to EBITDA, free cash flow positivity, free cash flow to dividend, payout ratio, dividend growth, bear case return, base case return, and probability of a 50% loss all pass. Trailing P/E versus its five-year average and forward P/E below 18 for new entry both fail. The trailing P/E of 29.95 sits above the five-year average of 24.06.

MarketBeat shows a consensus price target of $275.87, about 6.7% above the current price. Zacks reports an Earnings ESP of negative 0.80%, which raises the risk of a negative surprise in the next quarter. Short interest from ChartMill remains below 1% of float, with days to cover under 3.4. No short-squeeze or short-side catalyst exists.

The consensus bull case rests on the deep pharma pipeline and recent launches. The bear case points to MedTech weakness and elevated valuation. Both narratives are correct. The issue for new buyers is the current price, not the quality of the company.

Final Verdict: Johnson & Johnson stock analysis

This Johnson & Johnson stock analysis assigns a Hold classification because the $258.45 price eliminates the margin of safety that wealth preservation demands. The company passes the solvency, dividend, and downside protection estimates, but the probability-weighted return of 6.7% fails to clear the 7% hurdle with confidence. Under the neutral scenario, an existing position may continue to collect the 2.07% dividend, while a re-entry scenario near $220 is a modeling threshold rather than a recommendation.

For the full Johnson & Johnson stock analysis methodology and the complete Moschovakis Capital research framework, explore the equities library at moschovakiscapital.com/equities/.

Execution Infrastructure

For the execution of positions discussed in our research, we utilize the following institutional-grade platforms due to their regulatory compliance, liquidity, and reliability.

Risk Disclaimer: Past performance is not indicative of future results. Moschovakis Capital is a technology provider and research publisher, not a licensed financial advisor. Trading and investing in financial instruments involves significant risk of loss. Do not invest more than you can afford to lose. The analysis presented is for informational purposes only and does not constitute personalized investment advice.

eToro Disclaimer: eToro is a multi-asset platform. The value of your investments may go up or down. Your capital is at risk. Copy trading does not amount to investment advice. The value of your investments may go up or down. Your capital is at risk. eToro USA LLC does not offer CFDs. Do not invest unless you are prepared to lose all the money you invest.

Affiliate Disclosure: Some links on this page are referral links. We may earn a commission at no extra cost to you. This does not influence our analysis or recommendations.